Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00573859 · ClinicalTrials.gov registry record · Phase 1

The Reinforcing Mechanisms of Smoking in Adult ADHD

A Phase 1 study of ADHD, sponsored by University of California, Irvine.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT00573859 is a Phase 1 study of ADHD that has completed, run by University of California, Irvine. The registered enrollment target is 27 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00573859, a Phase 1 study of ADHD, has completed, sponsored by University of California, Irvine.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated. Smoking may be a form of self-medication in people with ADHD, which has specific reinforcing mechanisms such as improvement of ADHD core symptoms, enhancement of moods and arousal, or a combination of both. In addition, the reinforcing effects of smoking may be potentiated by stimulant medication. The study examined the reinforcing effects of ad libitum smoking with and without ADHD medication in adult smokers with clinically diagnosed ADHD. Participants were adults with ADHD. The effects of two day of ADHD medication compared to two days on placebo for were studied on nicotine intake (i.e., cotinine levels). In addition, task performance on the Continuous Performance Task and nicotine withdrawal symptoms were examined in response to ADHD medication + smoking a cigarette versus ADHD medication + abstinence versus placebo medication + smoking versus placebo medication + abstinence. The study identified the reinforcing mechanisms of smoking in interaction with ADHD medication. The findings will contribute to a better understanding of nicotine addiction and facilitate the development of targeted smoking cessation and prevention programs for individuals with ADHD and other people with deficiencies in impulse control and excessive risk taking.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG ADHD medication

Study Locations (1)

California

  • Department of Pediatrics - Irvine

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2006-09
Est. Completion 2010-06
Phase Phase 1

Sponsor

University of California, Irvine

368 total trials

What the Registry Record Tells You About NCT00573859

The ClinicalTrials.gov registry entry for NCT00573859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (86% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00573859 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00573859 about?

NCT00573859 is a clinical study titled "The Reinforcing Mechanisms of Smoking in Adult ADHD". Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated. Smoking may be a form of self-medication in people with ADHD, which has specific reinforcing mechanisms such as imp...

What is the current status of trial NCT00573859?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-09. Estimated completion is 2010-06.

What conditions does trial NCT00573859 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT00573859?

The interventions under investigation include: Placebo (DRUG), ADHD medication (DRUG).

Who is sponsoring clinical trial NCT00573859?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00573859 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.